ONCY and ONY Related Headlines
Go Back- Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
- Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
- Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
- Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
- Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
- Oncolytics plans FDA talks for pancreatic cancer drug trial
- Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
- Oncolytics Biotech regains compliance with NASDAQ minimum bid price rule
- Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
- Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
ONCY and ONY Related Press Releases
Go Back- Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
- Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
- Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
- Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
- Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
- Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
- Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
- Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
